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The .(2 part model)and medical costs seen from the perspective of the national payer
(HRQoL) (2 part model) intervention of survival, the Health Related Quality of Life
part econometric model is estimated which estimates the impact of the -A 5
RESPECT trial.  
role for econometrics is then derived and illustrated using the analysis of the 
ensitivity analysis.  A sto produce a probabilisticsuch as the requirement ,described
NICE and the influence they have on the requirements of economic evaluation is 
Net Monetary Benefit identified and defined.  The role of national bodies such as 
l Cost Effectiveness Ratios and care are outlined with key concepts such as Incrementa
The chapter is structured as follows: the objectives of economic evaluation in health 
national reimbursement bodies such as NICE.
ed ‘reference case’ framework of assessing and presenting evidence for highly specifi
where the emphasis is on structuring the econometrics such that it conforms with the 
econometrics may be used in the developing field of economic evaluation in health, 
to demonstrate the means by which advanced component is econdlyThe s
.of an important theme within national health care policy
thus, this analysis represents an economic evaluation ,such as community pharmacists
government to spread the burden of primary care on other health care professionals, 
standing policy of the current resources of GP time in primary care, it has been a long 
Given the increasing pressures on the limited .5 or more repeat prescriptionswith 
of Pharmaceutical Care (PC) in the management of the medications of elderly patients 
effectiveness analysis -a cost, ubstantive components.  FirstlyThis chapter has two s
Introduction2.1
Care for the Elderly
Effectiveness Analysis of Pharmaceutical -Cost2
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Typically this medication would be likely to secure higher returns if used elsewhere.  
ed to fund this particular available, partly on the basis of whether the money requir
can then choose which medications etc to reimburse, subsidise or otherwise make 
L ohigher salaries, etc.  A national body charged with maximising a populations’ HRQ
education schemes; paying nurses uses including pharmaceutical products; health
consistent meaningful comparisons across the whole spectrum of potential resource 
currency.  The use of generic measures of cost and benefit/effect potentially permit 
the national s used, typically measured inrce(QALYs) and a measure of the resou
Adjusted Life Years -, usually measured by patients’ QualityLoreturn in HRQ
interventions in health care has thus focussed on measuring an expected incremental 
ation of pharmaceutical products, medical devices and other Economic evalu
medication for one patient cannot be spent on the care of another.  
as a Pound, Dollar or Euro spent on providing care or -therefore the opportunity cost 
related quality of life subject to a fixed health care budget.  The cost concept is -health
health care, this often translates to a desire to maximise a population’s health or 
scarce resources with which to address unlimited needs and wants.  In limited and 
Economic evaluation addresses possibly the most fundamental problem in economics: 
General Objectives2.2.1
Economic Evaluation in Health Care2.2
very high value for future research.
translate to costly uncertainty (mostly around the health benefits) which implies a 
an observed within the trial.  However, the lack of statistical significance does th
effective -out may be more cost-life national roll-effective to treat, suggests that a real
-the fact that the econometric model suggests those at the margins are most cost
rmore, the limiting nature of the trial design in terms of population selected and Furthe
,000 per QALY, well within the levels stated by NICE.  0approximately £1
effective with an ICER of -costrecommendations, the intervention is found to be 
reference case model, which does not use statistical significance in its 
ss according to the NICE though the latter is not statistically significant.  Neverthele
to raise costs and improve the HRQoL research finds the PC for the elderly appears 
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McEwan, 2001).  Nevertheless, both cost effect and cost Levin andility analysis (ut
referred to as cost th, then such analyses should really be(QALYs) is used in heal
based effect -allocation of resources.  Note that as a utility,counterfactualultimately, 
potential and, would be achieved under one resource allocation and any other 
hat signifies the difference between outcomes t’incremental differencean ‘to.  Where 
is expected to make measured across the population the intervention is to be applied 
difference in effects against the mean incremental difference in costs an intervention 
l attempts to measure the mean incrementas analysiseffectivenes-In general, cost
aluesThreshold V
and Benefit-et: Ratios,  NffectsIncremental Costs and E2.2.2
incorporating model uncertainty (e.g. choice of survival models).
recent work is looking at formally model (as typified by standard errors) though more
i.e. uncertainty surrounding individual parameter estimates within the uncertainty
Typically this has been limited to parameter for resolving that uncertainty.  
tached to it, then there is little rationale something is very uncertain but has no value at
f .  Iuncertainty in the model) multiplied by the cost of making an erroneous decision
based on the probability of making an erroneous decision (which is based on the 
rationale underpinning this requirement is The value of resolving that uncertainty.  
quantify the uncertainty that surrounds the model or rather quantify the monetary 
requirement for economic evaluation in health, at least in the UK, is to A further 
ocess rather than to determine the decision.making pr-decision
the Thus, in practice, the main role of economic evaluation in health care is to aid 
alternative, national bodies may choose to reimburse almost regardless of the cost.)  
r any other treatments exist for a condition (if there is no other evaluation) or whethe
population (though this element could be formally incorporated into an economic 
whether the implied resource use may reduce inequalities in health across the 
factors may enter the decision maker’s decision making process, for example Other
after safety, efficacy and quality for purpose.hurdle
fourth called -the so–QALY has been aided by comparison to a reference cost per
9
confidence intervals difficult to construct.
effective or not and it is this property that makes meaningful -intervention is cost
know whether an negative.  Thus knowing the sign of the ICER is not sufficient to
intervention dominates usual care, note however that the ICER would again be 
If an intervention is both less costly and more effective then the provision.  
ention in favour of the usual care evidence clearly points to a rejection of the interv
and the intervention is dominated by usual care.  From a decision perspective the 
then the ICER is negative )0<(nd less effectivea)0>(is both more costly mics, a cost per QALY.  If an intervention intervention, and in the case of health econo
The ICER therefore gives an expected cost per unit of change as a result of the 
mean effect across population under usual care conditions=
mean effect across population under intervention conditions=
mean cost across population under usual care conditions=




expected incremental difference in the costs by the incremental difference in effect i.e.
Effectiveness Ratio (ICER), which divides the-is in the form of an Incremental Cost
evaluation. A common means of presenting the outcomes of an economic evaluation 
determined outside the economic often something that is of the effect explicit, but
value ry makes the issue of determining a monetaination of the two in practice)determ
which do not share the same metric (though there may be correlation between the 
The separation and comparison of outcomes into two separate conceptual components 
ce unit cost.  referen
monetary value via measuring the outcome in its natural metric and multiplying by a 
resource use such as nurse time or bed days in a general ward, may be converted to a 
tcome which has no obvious monetary measure.  On the cost side of the equation, ou
naturally measured in (or converted to) monetary terms (and labelled costs) and an 
utility analysis separate outcomes into an expected difference in all things that may be 
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historical spending i.e. what has been the previous cost per QALY of spending in the 
economic rationale (e.g. the shadow price) but rather an approximation based on 
idance are based not on question of interest.  The levels reported in the NICE gu
uch an ongoing appropriately set level (£20,000 to £30,000 per QALY) is very m
However whether the UK has an concern over the level of the threshold set.
rationing rather than a -be inherently anti) appearing toDaily Mail(notably the 
the general standpoint of the popular press learning process is just beginning with 
indicates that for the UK at least, the ,effective drug breached the threshold limit
this that jection of reimbursement on the grounds Herceptin and specifically the re
cancer ‘wonder’ drug appraisal of breast reaction to the publictheIn the UK 
learning process will continue.’
marketplace, it is possible that a general consensus will emerge.  Until then, the 
op experience in this new the medical profession and the general public devel
gain experience in allocating resources under increasing economic pressure, and as 
As public and private organizations cost in the absence of one, but concludes that ‘
budget constraint or the opportunity value, such as the shadow price of an explicit
a price for an intervention.  Weinstein suggests a number of ways of obtaining such a 
worth, is very explicitly separated from the mechanics of producing isan effectmuch
that the decision of how benefit, is -utility) over cost-effectiveness analysis (or cost
-’  Thus a benefit of costconsideration of unquantified factors must come into play.
making context, judgement and -regardless of the decisionand that ‘number’
‘any algorithm for calculating such a nor of no magic number’that he knows of ‘
) argues 1998(Weinstein ceiling value), (a.k.a. threshold value or	
 In 
(2.2) 
effective if:-, then an intervention may be considered cost
effect i
decision maker’s maximum willingness to pay for an effective.   For example, if a
-costis an intervention whether order to determine whether an ICER indicates 
maker’s monetary value of a unit of effect, which needs to be explicitly specified in 
difference in effect?  The answer will depend on the decision difference and a positive






across the population:competing technologies
differences between expectations or averages of outcomes and resource use for 
NMB into INMB may be written in a manner which splits the IAs with the ICER, the 
(2.4)0>C
E=
and so the decision rule is: 
b
incremental cost NHB) which divides the INet Health Benefit (Incremental And the 
(2.3)0>
=
:and so the decision rule is
multiplies the incremental effect b
NMB) which INet Monetary Benefit (Incremental formulisations are suggested: the 
ero.  Two benefit is greater than z-effective if the net-intervention is considered cost
benefit framework suggests a subtle reworking of the decision rule such that an 
-).  The netcit, opet alconfidence intervals for ratios has well known problems (Hoch 
producing when it comes to capturing the impact of uncertainty as, for example,
benefit approach is suggested as an improvement over the production of ICERs -net
, 2002).  The et albenefit approach (Hoch -decision making is in the form of the net
er amenable to aiding effectiveness analysis in a mann-presenting the results of a cost













evaluation process is recognised and likely to be a research priority over the coming 
tainty in the The need to address this rather important but neglected uncerNHS?
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limited budget.  As such it presents a set of rules and methods which should be 
sparent and consistent with the NHS objective of maximising health gain from a tran
reference case model is there to ensure that methods used are valid, unbiased, 
The .(NICE 2004)as outlined in the ‘Guide to the methods of technology appraisal’
At the heart of the NICE technology evaluation process is the ‘reference case’ model 
.2003)(
et al Hill an obvious recognition of their credibility.’–international benchmarks 
are already being used as [which]technology appraisals internationally … 
represent an important model for the NICE appraisal process found that it does ‘
review of In addition a World Health Organization (WHO)Netherlands and Sweden.
tional bodies with similar functions exist in Scotland, Canada, Na.population
for the relevant effectively defines demand for medications it has reviewed
ce, to all intents and purposes, constraints that bind PCT spending, NICE guidan
by NICE within 3 months of the guidance being issued.  And given the financial 
resources in England and Wales for medicines, devices and treatments recommended 
has been legally obliged to provide funding and Since January 2002, the NHS
with specific diseases and conditions within the NHS.
guidance on the appropriate treatment and care of people -clinical practice 
treatments and procedures within the NHS
guidance on the use of new and existing medicines, -es health technologi
and voluntary sector
ill health for those working in the NHS, local authorities and the wider public 
guidance on the promotion of good health and the prevention of -public health 
NICE produces guidance in three areas of health:
health.of ill 
on the promotion of good health and the prevention and treatment England and Wales 
in NICE is the independent organisation responsible for providing national guidance 
ole of NICERThe2.2.3
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legitimate reference for the Committee.
with other programmes that are currently funded are possible and are a 
comparisons of the most plausible ICER of a particular technology compared 
inappropriate, below which it would. … Although the use of a threshold is
which a technology would automatically be defined as not cost effective or 
6.2.6.7  The Appraisal Committee does not use a fixed ICER threshold above 
uide as follows:gspecified within the 
lues is effectiveness.  This range and adoption of threshold va-to rule in or out cost
a range of values beyond which rather substantial external factors would be required 
accordance with Weinstein this is not a single absolutely determining figure but rather 







e following key principles which models should are based on thproduction processes 
NICE guidance as whether to use a markov chain or decision tree model, however, 
such –The methods guide does leave some degree of freedom in many model options 
effectiveness plane. 
-CEAC) and scatter plots on the costEffectiveness Acceptability Curve (-a Cost
combined implications of uncertainty in parameters and the outcomes demonstrated in 
(PSA) should be conducted on models to reflect the Probabilistic Sensitivity Analysis
Effectiveness Ratios (ICERs); -remental Costoutputs should be summarised as Inc
be viewed from the perspective of the NHS and Personal Social Services; model 
5D); discounting should be at 3.5% p.a. for both costs and QALYs; costs should -EQ
expressed in QALYs derived from validated instruments (e.g. outcomes should be
adhered to unless there are substantial mitigating circumstances. For example, 
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Not only are NICE standard.’presently undeveloped or where there is no agreed 
is ’ especially in areas of technology appraisal that ‘methods of technology appraisal
further development of the methodology rapidly developing, NICE are amenable to ‘
assessment is relatively young and the However, as the field of health technology 
for a NICE rejection on exactly such grounds.
2003) (et alSee Clark effect with no empirical (trial based or otherwise) justification.  
aceutical company has made a favourable assumption of the length of a drug a pharm
may lead to an analysis being rejected: for example, where an industry submission by 
measures), legitimate justification is required.  Failure to conform to the guidance 
iations from the reference case are permissible (e.g. disease specific outcome var
And although )outputs, relevant comparators, time horizons, etc.be assessed (e.g. 
are to explicit details on the means by which new technologies in England and Wales
The guide not only contains the notional range of threshold values but contains very 
have been taken into account, in the ‘Considerations’ section of the guidance.
l be explained, with reference to the factors that the Committee’s decision wil
technology on these factors has to be increasingly strong.  The reasoning for 
6.2.6.11 Above an ICER of £30,000/QALY, the case for supporting the 
Where appropriate, the wider societal costs and benefitso
technology
eceiving the The particular features of the condition and population ro
The innovative nature of the technologyo
The degree of uncertainty surrounding the calculation of ICERso
reference to factors including:
ive use of NHS resources are more likely to make more explicit as an effect
ICER of £20,000/QALY, judgements about the acceptability of the technology 
effectiveness estimate.  Above a most plausible -based primarily on the cost
the acceptability of a technology as an effective use of NHS resources are 
judgements about 6.2.6.10 Below a most plausible ICER of £20,000/QALY,
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guidance and now has several explicit mentions:
to the reference case model in the technology assessment update to the original 2001 
tic sensitivity analysis was added as a requirement thinking.  For example, probabilis
responding to academics’ (and perhaps to economists in other fields, controversial) 
hypothesis testing.  Arguably it is this shift that shows that policy makers are 
analysis combined with a lack of emphasis on traditional probabilistic sensitivity 
notably a shift of emphasis to–in health from other branches of economics 
treatment of this uncertainty which probably most distinguishes economic evaluation 
, 2005).  It is the et alainty contained within the evidence (Claxton in the face of uncert
the growing awareness of the role of economic evaluation in aiding optimal decisions 
he emphasis on PSA is a fairly recent change to the NICE methodology and reflects T
industry submission to NICE.  
is) is a formal requirement of any (never mind simple univariate sensitivity analys
op cit).  However, in NICE guidance, probabilistic sensitivity analysis (and McEwan
Levin is less common than its importance dictates’ effectiveness texts, but in practice ‘
-ivity analysis is stressed in costsensitivity analysis (PSA). The importance of sensit
economic evaluation is relatively more advanced is in the area of probabilistic 
attribute outcome measure in education.  Another area in which -utility based multi
tives.  For example, there is no generic many of the fundamental concerns and objec
arguably more advanced than it is in related fields such as education, despite sharing 
As a result of this openness to academic thought, economic evaluation in health is 
tive definition of appropriate methods.’prescrip
authority demanding formal economic analysis of new technologies based on a highly 
making -appraisal process in the UK provides the most stark example of a decision
The NICE technology argues that ‘(2005)s such, SheldonA.other areas of research’
concern has been that it is distorting the balance of health economics away from
executive board, to its secretariat …that a real -so many economists into its non
has drawn argues that NICE ‘(2005)considerable academic presence.  Indeed Buxton
contained a Methodology Working Party and four Task Groups which have
methods and, indeed, this current published guidance has been heavily influenced by a 
s further research into new in recognised areas, it promoteamenable to innovations
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Claxtonstatistically significant or fall outside a Bayesian range of equivalence’
(posterior) mean net benefit irrespective of whether any differences are regarded as 
should be selected on the maximise health gain for a given budget, then programmes 
coherent health care system and impose unnecessary costs.  If the objective is to 
Bayesian counterpart are arbitrary, are inconsistent with the objectives of any 
ssical statistical inference and its the rules of cla…‘, thendecision making tool
he case that as economic evaluation is essentially a strongly teconomists have argued 
The reason for the omission of inference/ statistical significance, is that many health 
econometric significance testing.  simply finds no formal role for statistical/
silent on the appropriate level of statistical significance as befits a document that 
levels of discount rates to be applied to costs and benefits over time, it is entirely 
document is very prescriptive in say, within the entire document.  And whilst the
mention of ‘hypothesis test’, ‘hypothesis testing’, ‘statistical significance’ or similar 
and synthesising evidence on the technology being appraised.  Contrast this with zero 
e appropriate methods for assembling analysis within the chapter which deals with th
references to probabilistic sensitivity are some eight separate bullet pointIndeed there 
effectiveness acceptability curves.-effectiveness plane and cost
-re confidence ellipses and scatter plots on the costof presenting uncertainty a
cost effectiveness of the options being compared.  The most appropriate ways 
imprecision in all input variables into a measure of decision uncertainty in the 
…. Probabilistic sensitivity analysis should be used to translate the 5.9.3.1
use of probabilistic sensitivity analysis.  
parameters can simultaneously be reflected in the results of the model by the 
technology before making the decision.  The uncertainty associated with 
ble to ascertain the true cost effectiveness of each reached if we were a
that is, the probability that a different decision would be –with a technology 
5.8.4 It is important for models to quantify the decision uncertainty associated 
reflect the combined implications of uncertainty in parameters.
models to 5.8.1 … Probabilistic sensitivity analysis should be conducted on 
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(CEAC).  
Effectiveness Acceptability Curve -y a Costeffectiveness plane and/or b-the cost
ellipse on -degree of uncertainty surrounding an ICER be represented by a confidence
NICE recommend that the techniques which may be unfamiliar to general economists. 
on PSA motivates further detailed discussion of the The emphasis that NICE places
Probabilistic Sensitivity Analysis2.2.4
an EVPI requirement is somewhat surprising.
relatively small jump from PSA and thus the lack of acalculating the EVPI which is
ow in the next section there is a method of rch?  As I will shvalue future resea
favourable ICER? And why does the reference case model not require submissions to 
uncertainty would cause decision makers to reject an intervention that had a 
what level of NICE guidance is rather quiet on both these issues.  For example
However the .also in the initial decision as to whether or not to adopt the technology
, but a separate decision about the value of acquiring further informationinforming
as The quote illustrates that the uncertainty enters at two points, most distinctly 
additional evidence required to support the adoption or reimbursement decision?’
the current uncertainty surrounding outcomes and resource use? …Secondly, is 
a technology be adopted or reimbursed given the existing evidence and Firstly, should 
distinct but simultaneous decisions that must be made within any health care system.  
There are two conceptually explanation, ‘the followingprovide (2006)et alClaxton
what exactly is the motivation for its prominence in the NICE guide?technology, then
uncertainty is obvious: if uncertainty is not to be used in accepting or rejecting a new 
statistics or econometrics in the traditional role of hypothesis testing where the role of 
ing puzzle for anyone who has been primarily trained to use So this leaves an interest
.alternative treatments/technologies
simply based on the expectations of the difference in the costs and benefits of 
result of some statistical test based on arbitrary level of significance, but instead 
ective or not, is not the eff-1999).  That is, whether a technology is considered cost(
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been willing to pay for such a (positive) change in effect.
reduction in effect comes with a cost saving that is in excess of what they would have 
effective if the -this also makes less effective interventions costeffect.  Notice that
which is less than the decision maker would have been willing to pay for that size of 
costly, more effective) the increase in effect has come at an expected increase in cost 
nt) as even for those ICERs in the upper right quadrant (more of the upper left quadra
effect (note this includes the whole -ICERs to the left of this line are considered cost
by the dashed line).  (shown
via a line which intersects the origin and has the slop
effectiveness plane -t may be incorporated into the costwillingness to pay for an effec
effective new treatment.  The -required to know whether the evidence points to a cost
, is 
circumstance some knowledge of the maximum willingness to pay for an effect
quadrants.  In such the upper right and lower lefter ofICER lies within eith
therefore dominated by the conventional treatment.  It is not so straightforward if an 
the second instance, the new treatment is both more costly and less effective and 
ess costly and therefore dominates the conventional treatment. In more effective and l
implied decision is straight forward.  In the first instance the new treatment is both 
If an ICER falls within either the upper left or bottom right quadrants, then any 
.effective but less costly
tains technologies which are both less more costly; and the lower left quadrant con
costly; the lower right quadrant contains technologies which are less effective and 
upper left quadrant contains ICERs for technologies which are more effective and less 
both more costly and effective; the ed isew technology being assesswhich imply the n
is generally divided into four quadrants.  The upper right quadrant contains ICERs 
, the plane or negativezero,benefits can be positiveincremental and scostincremental 
s both Aepresents one plot on the plane.such that each paired draw r(x axis) 
(y axis) against incremental costs /effectincremental utilitysimulated or bootstrapped 
carlo -paired monteplots) 1-Figure 2(as shown ineffectiveness plane -costA 
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-NMB has the CostIeffectiveness plane, the -ar.  Instead of a costincreasing popul
NMB approach is becoming IPartly as a response to both of those questions, the 
the point of a 95% confidence interval?
) and secondly, given the ‘irrelevance of inference’, what exactly is op citet al (Hoch 
c the ellipse may be problematione quadrant of the plane, the actual construction of
This however leaves two issues.  Firstly, where the simulated ICERs cover more than 
effectiveness place and a 95% confidence ellipse constructed.  -plotted on the cost
d.  The simulated ICERs may then be strappe-data) and new ICERs simulated/boot
strapped from patient level -according to the distributions implied by the data (or boot
effectiveness plane as follows: incremental costs and benefits may be simulated 
-vity analysis may be demonstrated on the costThe impact of probability sensiti
decision maker’s willingness to pay for that size of effect.
difference on effect but come at an expected incremental cost which exceeds the 
dashed line are those interventions which have an expected positive incremental of the
right quadrant.  Those ICERs that are in the upper right quadrant but fall to the right 
this contains the whole of the lower eeffective, again not-evidence imply are not cost
those ICERs which fall to the right of the dotted line are those which the Conversely, 
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effectiveness.-would meet the NICE criteria for cost
effective for threshold values above £20,000 it -as the intervention is probably cost
it will asymptote to values above 0.5.  For this particular example, effect, means that 
effective for very high values of -it is more effective and likely to be found as cost
effective when the effect is valued low and hence starts at or near the origin. And that 
-ntervention is more costly means it is less likely to be costmore effective.  That the i
would represent a CEAC for an intervention that was both more costly and 2-Figure 2
.(without having to repeat the simulation) gives the full CEAC
ofating across all relevant levels.  Repe
 lity is obtained for that level oprobabi
exercise across all of a sufficient number of simulated values, then a measure of the 
effective.  If one does this -considered higher), then the intervention is considered cost
higher than the cost (even if both are negative, where closer to zero is benefit is 
if money valued –monetary valued incremental effect against the incremental cost 
, then compare pairwise, the 
 simulated benefits and multiply them by a give
summarising uncertainty.  To plot a point on the CEAC one can simply take the 
tation coming in the step that translates the simulation results to the graphical represen
or boot strapped distribution of costs and benefits.  The difference between the two 
construction of a confidence ellipse for ICERs by involving a Monte Carlo simulation 
he axis.  In practice, construction of the curve is very similar to that involved with t-x
on the 
axis agains-effectiveness on the y-does so by plotting the probability of cost
fective for different levels of a maximum willingness to pay for an effect.  It ef-cost
probability that, given the statistical evidence, an intervention or new treatment is 
CEACs show the .such as the British Medical Journalseconomics publication
-now reached such a degree of acceptability that they now commonly feature in non
have ) 1994(et alattributed to Van Hout CEACs, oftendemonstrating uncertainty.
Effectiveness Acceptability Curve (CEAC) as its analogous graphical tool of 
21
research.  
as a means of valuing further -ythe other rationale for incorporating uncertaint
NMB approach is also useful in understanding IThe CEAC and .  intervals for ICERs
So CEACs avoid the computational problems involved in constructing confidence 
uncertainty.
mity to 0 and 1 will depend on the .  And, as discussed, the proxis0.5 a and asymptote to a value above 0=t then CEACs will originate below the 0.5 line a
generally if an intervention is expected to be both more costly and more effective, 
discuss these issues in far more detail, but 2004)(et alFenwick dummy variable.  
value surrounding the intervention -pis the e , wher2
1will asymptote to
show that the CEAC ) (2002et alors capture the parameter uncertainty, then Hoch err
example if a linear regression model is used to estimate the effect and the standard 
estimations and the uncertainty surrounding the estimates of effects and costs.  For 
Where the curve will originate from and end up is naturally closely associated the 
: Example CEAC2-2Figure 
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assumptions, is only a small additional step.  Since the empirical component of this 
intervention and simulated a CEAC, calculating EVPI, even without parametric 
NMB of an IFurthermore, having calculated the the next round of revised guidance.  
require a measure of EVPI.  This remains a paradox which may well be addressed in 
the NICE Guide. I.e. whilst the NICE reference model requires PSA, it does not 
it is therefore puzzling to find no reference to EVPI in further evidence is available,
NICE do indeed make reimbursement decisions and then do revisit them later when 
second criteria (is further evidence needed to revisit this decision?) and given that 
s testing, but presumably as a means of informing Claxton’s means of hypothesi
Accepting that the NICE rationale, as evidenced in the ‘Guide’, values PSA not as a 
.the decision to be revaluated
recommendation to permit the pharmaceutical under limited conditions, but also for 
with a op cit)(t aleuated in Clark Infliximab in the treatment of Crohn’s Disease, eval
further information is available.  In practice this does occur, for example the use of 
current reimbursement position but also make a decision to revisit the evaluation once 
still make a decision on its effectiveness and a high EVPI but-surrounding the cost
example, NICE could evaluate a technology, find there is a great deal of uncertainty 
pay for further research and thus also a means of prioritising research.  So, for 
cision makers should be willing to therefore represents a theoretical maximum price de
is zero (cost of an error * a zero probability of making an error).  The EVPI also 
error * probability of an error) and the expected cost under perfect information, which 
n current information (cost of an difference between the expected cost of an error give
probability of making a mistake reduces to zero.  The EVPI is therefore simply the 
Expected Value of Perfect Information (EVPI), as perfect information implies the 
urther evidence.  This is known as the reducing the uncertainty by obtaining f
function of the evidence, then the expected costs place an upper limit on the value of 
of the uncertainty surrounding the parameter estimates) and the uncertainty is a 
probability of making a mistake (i.e. a function making a mistake is a function of the 
As the expected cost of .respectivelythe probability of making an incorrect decision
show the costs of an incorrect decision and NMB approach and CEAC Imistake. The 
) and the probability of making that 
a function ofunction of the cost of a mistake (
expected costs of making what turns out to be an incorrect decision; which in turn is a 
In general, the value of acquiring further information is essentially derived from the 
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where,},…,3,2,1{eachfor that may be treatedpopulationant relevof the 
a member is defined for streatmentfor each ) ,( Benefit MonetaryA Net
given population may be written as follows:
Formally, the decision facing any agency responsible for maximizing the HRQL of a 
ModelaseCeference NICE Rtheonstruct of CFormal2.2.5
mention them only for completeness.
.  Such models are beyond the scope of this thesis and I such as the Gaussian Process
m, led economists to seek means of modelling the outcomes rather than simulating the
tational expense of EVPPI has requires simulations within simulations.  The compu
as it expected cost and outcomes is not linear, for example in Markov models’ 
computation for models where the relationship between the parameters and the 
does require substantial additional ‘EVPI, EVPPIconceptually similar to
although (2006) argue that et alClaxton useful than simple EVPI.  However 
used to identify where future research should be concentrated and is arguably more 
t; the effect on QALYs; the difference in costs; etc.).  EVPPI may then be treatmen
effectiveness model (e.g. the time horizon of the -the specific parameters of a cost
the partial EVPI.  This concept places a value of resolving the uncertainty surrounding 
ected Value of Perfect Information for a Parameter(s) (EVPPI) also known as the Exp
A final ‘expected value’ concept which has entered the field of health economics is 
cost, etc.
the cost of increasing sample size in a study is matched or exceeded by additional 
mum price for a research proposal or can be used to determine whether gives a maxi
endpoints, etc.) to work out the Expected Value of Sample Information (EVSI), which 
information methods may be applied to a proposed research design (sample size, 
h is unlikely to be able to promise absolution to that degree.  However value of researc
willing to pay for further research which resolves all uncertainty.  In practice, further 
represents a theoretical maximum amount a decision maker should be thus The EVPI 
the computation technique till then.
, I leave a more detailed discussion of chapter will contain a fully worked illustration
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balanced.
effectiveness analysis, but may be influential when a decision is finely -cost
This parameter is not usually incorporated in a NICE .population member
rameter is assessed across the expected life time of the representative pa
, this and some direct costsAs with HRQoL.foregone income due to illness
such as ,the expected indirect costs from an individual’s perspective, !
may be subject to change.
his position is not universally agreed by the NICE technical committee and t
they should not be included though from private correspondence I note that 
costs may not always be considered. Current NICE guidance suggests that 
Any direct costs related to the disease should be included but other ‘unrelated’ 
. ifetime of the individualassessed over the lusually costs are not all,HRQoL
, excluding the treatment costs. Unlike sunder treatmentithe individual
by medical costs (from the payer perspective) createdhe expected direct , t !"
events linked to the treatments.  of adverse probability
due to expected differences in life span, quality of remaining life, or the 
effectiveness analysis. Differences in utility across population types may occur 
-as it represents ‘the effect’ in a costE is conventionally donated by an 
xpected HRQoL and future health discounted by 3.5%. The eYears (QALYs)
reference case model, HRQoL will be measured in Quality Adjusted Life 
Following the NICE the representative individual. expected lifetime of 
strategy is to be implemented and also measured over the treatmentwhich the 
individual in the population in the year in thethe expected HRQoL for , !
are:The parameters contained in
s.eis considered in probabilistic sensitivity analys
easured with varying degrees of uncertainty, the impact of which are mcontained in
he parameters . It should be noted that trisk typesandmay vary across population
effectiveness parameters with values which -represents a vector of appropriate cost
25
:following decision
effectiveness, the decision maker is facing the -in terms of cost. Therefore,benefit
that maximises the total population aggregated or population averaged net treatment
, is thus the #,treatmente optimal xpectation, thaveraged e-obtained a population Having N.s from the population 1 to $ represents a matrix of the individual






tive individual.a representative population rather than a representa
averaged across the whole population, it is therefore important to assess the NB across 
benefit for the average patient may not equal the expectations -linear models, the net
-parameters are defined in nondifferent age; sex; baseline risk). As several of the 
assessing the argument across a defined collection of representative individuals (e.g. 
These net benefits may be applied to a population of heterogeneous patients by 
.sassociated with treatment iindividual 
for and represents the composite cost parameter !+ !"+ !(= !Where 
(2.7) !
 !=) ,( 
Or more simply as:
(2.6)) !+ !"+ !((
 !=) ,( 
us given by:is thfor the representative individual sB of any strategy MNThe 
, individuals, and possible treatment optionsassumed constant across time
This is .the decision maker’s willingness to pay for an additional QALY
.iindividual
for the sreatmentstof implementing scosteatment trthe expected , !(
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B will be negative. MNI, the 
ICER exceed
B will be exactly zero and if the MNI, the 
ICERB will be above zero, if the MNI
, then the 
 B approach, if the ICER is beloMNITo draw equivalence with the 
attractive especially when probabilistic sensitivity analysis is required.
this simple means of comparison that makes the net benefit framework nd it is A
(2.11)]0,),(![)E!ArgMax=#
are negative), is equivalent to maximising the NMB.
With a common comparator, maximising the INMB (or taking zero, the baseline, if all 
effectiveness will be.-the larger the difference in cost
de of the INMB, maximum willingness to pay for the effect. The larger the magnitu
effective given the -equivalent; and less than zero, the comparator is more cost
s are treatmenteffective; equal to zero the -other common comparator is cost
being compared to the baseline or treatmentIf the INMB is greater than zero then the 
(2.10)),*(
),(=+!,!
’s NMB and the baseline’s, i.e.,ference between the new treatmentdif
is simply given by the treatmentthen the INMB of any other atmentcomparator tre
thus common andas the baseline treatment*. If we definedtreatmentstwo 
Net Benefit (INMB), which is defined as the difference between the NMBs of any 
An alternative way of looking at the decision problem is to calculate the Incremental 
averaged net benefit.-maximises the total or population
which, given the expectations of the uncertain parametersstreatmenti.e. choose 
(2.9)]),(![E!ArgMax=#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but also those future patients who may benefit from the treatment.  They argue that 
argue that population of interest includes not only all current patients, et aland Briggs 
ary of interest However, it is the EVPI summed across the population that is the summ
EVPI per patient.  
Averaging across all simulations gives the population averaged EVPI or average 
. ),()E!max>),(!maxto the difference between the two where 
is equal the opportunity loss,the parameters meant that the other choice was optimal
.  If however the realisation of ),()E!max=),(!maxloss is zero i.e. 
simulation choice, then the treatment choice is the correct one and the opportunity 
averaged Where the individual simulation choice equals the.),(!max
option would have been the best for that realisation of the world i.e.  
One can then look over all the simulations and choose which .),()E!max
according to effective i.e. choose sost cost which treatment is on average the m
one can determine 

necessary for construction of a CEAC, then for a given value o
possible to obtain a measure of this.  For example, having conducted the simulation 
Having simulated incremental outcomes it is maximum expectation of the NMB.  
That is the EVPI is equal to the expectation of the maximum NMB minus the 
(2.12)),()E!max
),(!max)E=-.
he EVPI is given by:2006) show that t(et alBriggs 
.
the societal maximum willingness to pa(univariate) sensitivity regarding
Effectiveness Acceptability Curve which has the additional benefit of incorporating 
-a CostasThe impact of such uncertainty is usually presented .uncertainty
work is most amenable to demonstrating the impact of parameter B frameMN
economics decision making framework, the -recognisable and requested in a health
straightforward, whilst the ICER is the summary measure that is most immediately 
The answer is .necessary to formulate the decision framework in two analogous ways
is Indeed one may question why it .optimal strategy will be the same in each case
Given the equivalence of the two approaches there should be no surprise that the 
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.  Firstly and possibly most importantly, ory of using econometric modelsa greater hist
There is an interesting contrast with economic evaluation in education where there is 
SA.averaged outcomes and input for P
The difficulty involved in converting econometric results into population 
to making predictions on the original scale.
tests and so an emphasis on models and techniques which are not so amenable 
eans to conduct hypothesis The use of econometrics by practitioners as a m
less need for more complicated econometric techniques.
of effect.  As confounding effects are balanced by the randomisation, there is 
permits simple comparison of treatment and control arm means as a measure 
The prevalence of Randomised Controlled Trial clinical data in health, which 
Additional reasons may be: 
based methods.  -regression
The main statistic of interest, the ICER, being a ratio, is not amenable to 
est that the main reason for this is that: sugget alHoch 
the economist’s main statistical toolkit within economic evaluation in health care. 
2002)  identify a lack of use of (et alHochthus mainstream econometric techniques’
Evaluation is often seen as a branch of health economics divorced from ‘Economic 
Economic Evaluation(Health) The Role of Econometrics in2.2.6
Where r = discount rate (NICE state a rate of 3.5%)
(2.13)%/0 /)1+1(//2.EVPIEVPI for the population =  
) and that:  tIestimates of incidence over this period (
), and Tology (this requires some estimate of the expected lifetime of the techn
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constructed.  That is, it must be: 
ly developed framework that health economists have must be geared to fit in the high
However in order for econometrics to reach its potential in economic evaluation it 
comparisons.
A means of combining data from separate trials e.g. mixed treatment 
selection models.-self
iable techniques or Heckman style which may be addressed by instrumental var
random attrition -selection issues such as non-A means of correcting for self
whose characteristics are different to those which generated the data
extrapolating over increased time horizons or across a population A means of 
benefit from the technology.)
subgroup analysis (e.g. 2.2.1.1 the capacity of different patient subgroups to 
An increasing interest on heterogeneous effects across a population or 
echniques which can eliminate confounding factors.implies a bigger role for t
randomised trial data -sources including observational data.  The use of non
effectiveness models often draw evidence from a number of -Complex cost
to be:
ic models in economic evaluation in health, the main reasons would appear econometr
There has, however, been a growing awareness of the benefits of implementing more 
, there would appear to be little cost in using econometrics.)from hypothesis testing
and away (tion has not (yet) reached the same emphasis on predictions and PSA educa
And on the ‘cost’ side of using econometrics, as economic evaluation in .models
difference -in-regression methods are an obvious solution, in particular difference
econometric –accounting for confounding factors lest omitted variable bias occurs 
for there are relatively very few RCTs in education and so some means is required 
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illustrates this issue.3-Figure 2.averaged across the relevant populationeffect
evaluation is concerned with an specific effect, whereas economic-produce a subject
ric model will econometlinear-t the coefficient produced in a nonevaluation in tha
This has a major implication for economic .the other covariates (Ai & Norton, 2003)
incremental effect of a technology on the original metric will not be independent of 
and therefore the linear (any of the standard link functions other than the identity link) 
-However GLM regression models tend to be non.  framework, are often justified
models, or GLM in a panel data odels (GLM)Minear Leneralized the use of G
s awkward in this sense and so .  And cost and QALY data are almost alwaymodels
linear -and lead to nonzero (or a boundary at 1 for QALYs)-skewed, strictly non
are forward when the original data are awkward i.e. demonstrate heteroscedasticity, 
the original metric is not always straight dentification of the incremental effect onI
latter half of requirement 1 which causes the most substantial changes.  
) it is the where substantial changes are impliedmore than a difference in semantics
effect, rather than the marginal effect (which is alincrementevaluation is about the 
the usual hypothesis test).  And although economic least, place less emphasis on
ignore or, at the very change to usual practice (with the exception that we simply 
would therefore require little effect of a variable whicharginalidentification of the m
Requirement 1 would seem to coincide with the core objective of econometrics, 
Able to compute Expected Value of Information calculations.3.
Effectiveness Acceptability Curves-production of Cost
bility sensitivity analysis and Amenable to the requirements of proba2.
averaged across a population measured in terms of QALYs and costs.
A means of identifying the incremental effect of a technology, 1.
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and though there is 2345 5678676same as the expectation of the average effect i.e.
linearity is that the average expected effect is not the -The consequence of the non
.2elarger incremental change in probability of 
individual in the population, has a much average, in many respects the individual 2
whereas 3eand e1of 3shows two small changes for individuals 1 and diagram 
The not translate to a shared consistent shift on probability scale for each individual.  
scale does 9:e .  However the effect of this consistent shift on th:consistent amount
scale by the 9:the effect on each individual will be to move them all along the Thus .:regression model has identified an incremental effect of an intervention of
scale at positions i1, i2 and i3.  Suppose the 9:place them on the characteristics Now suppose there are three individuals in the population whose individual 
to a probability, a metric with a policy relevance.  9:maps the linear combination .  The familiar sigmoid ranging from 0 at the base of the axis to 1 at the topaxis-the y
probability of a positive response (of say achieving a remission in a given month) on 
axis and the -located on the x9:model with logita standard represents3-Figure 2
Linear Model-in a NonmpactsIncremental Iiffering Dxample of E: 3-2Figure 
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covariance matrix may be used to simultaneously draw all parameter -of the variance
in a meaningful manner.  Use to the original metric and demonstrate the uncertainty
parameters simulated from an appropriate normal distribution may then be converted 
Thus may assume approximate normality of regression coefficient estimators.’
Thus, if sample sizes are large, then we be expressed as weighted sums of responses. 
improves as the number of random variables increases.  Regression coefficients can 
variables are approximately normally distributed and that the approximation 
hich roughly state that weighted sums of independent central limit theorems, w
This premise is reasonable because of the ‘Frees (2004) argue that regression) and 
assumption that underpins standard hypothesis testing in same (and this is the 
ed, it is assumed that the regression coefficients approximately are normally distribut
data indicates they may be.  Although the outcome on the original metric may not be 
simulate alternative values for the parameter estimates with the likelihood that the 
sure of the uncertainty surrounding the point estimate, one may then errors as a mea
variables, but also the standard error of those estimates.  Treating these standard 
example, regression equations produce not only point estimates of the effect of 
uirements 2 and 3, are related and also pose no practical restrictions.  For Req
general population in certain characteristics.
if it is known that sample population differs from the 9marginal distribution of generates the conditional distribution, one could even apply this to a different 
lation.  Indeed as the regression method out the general poputhrough9distribution of estimate the conditional expectations may be used as a representative sample of the 
especially if the data used to ,a fairly trivial steppotentially is 9distribution of onditional expectation and a marginal given the c;marginal distribution of 
.  However the step from generating expectations from the 9marginal distribution of the andwhich is a function  of the econometrically derived conditional expectation 
,;in the mean of the marginal distribution ofdecision makers are more interested , 9no;states that whilst econometricians focus on the conditional expectation of
values of the explanatory variables will not suffice.   In statistical terms this argument 
a meaningful scale at evaluated at average coefficients or coefficients converted to
of primary interest to decision makers acting on behalf of society.  Thus a table of 
some interest in the variation of the effect, it is the former rather than the later that is 
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be willing to pay to resolve this uncertainty.  This exercise may be repeated for 
of £100 per patient and thus represents the maximum value a decision maker would 
This leads to an average value of loss cases, the decision would have been incorrect.
is correct and the simulated realisation of the world leads to no loss, but in 10% of 
In 90% of cases the decision .per patientintervention is cost reducing, by say £1000
ave thrown up 10% of cases where the intervention, however the simulation may h
simulations.  For example at a MWTP of zero, the data may point to a rejection of the 
inconsistent with the final decision and then averaging this value across all 
determining the INMB for each simulation which is This is constructed by 
estimate of the EVPI.  analso be used to construct microsimulation results may The 
range.
can be used to construct the whole CEAC over an appropriate 
differing levels of
.  Conducting this exercise for 
e for that level oeffectiv-that an intervention is cost
NMB is positive may then be used to plot the probability Isimulations for which the 
NMB for each simulation.  The proportion of Iand therefore work out the 
a value of
h iteration and multiply the incremental QALYs by sufficiently large, one can take eac
Repeat steps 1 to 3 for a sufficient number of simulations.  Once the simulation set is 
QALYs.
over population to obtain population averaged incremental effects on cost and 
for expectations for individuals and average Convert to the original metric3.
individuals within a population.
Apply the drawn parameter values to the fixed characteristics of the 2.
realisation of the world; 
covariance matrix, treat this draw as a one possible -parameters and variance
from the regression Sample new parameter values for all parameters 1.
model, one can: 
So in practice, in order to conduct a PSA and construct a CEAC from a regression 
the true values is essentially a Bayesian view of what is a frequentist technique.
ure of the probability of Note however, the treatment of the standard errors as a meas
variables in a model thus accounting for correlation between parameter estimates.  
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are perhaps more in need of improved prescribing than those in younger age groups.
2003). Therefore, the elderly population ,et alrug therapy (Crealey to problems with d
been reported that as many as 31% of geriatric hospital admissions are directly related 
1995). It has also ,has been estimated at $76 billion annually (Johnson and Bootman
2000), the cost of which ,et alThomas 1998;,et alGray 1991;l,et a(Leape treatment
his includes both over and under tpriate medication,people may receive inappro
p to 80% of elderly and urelated adverse events -are more likely to experience drug
s a result, elderly people and a1996),(Zermanskym75% of theroximately review app
doctors are believed to only Of these repeat prescriptions,see the doctor.required to 
being issued without the patient -often re1997). These are prescriptions that are 
,ptions for older people are repeat prescriptions (Royal College Physiciansprescri
pproximately 78% of an aand 59 years) -5than younger adults (those aged 1
n average those aged 60 or over have 3.6 times more prescriptions ocounterparts:
than their younger re prescribed a greater number of medications diseases and a
e chronic mormknown to suffer froareUK population Members of the elderly 
BackgroundTrial 2.3.1
RESPECT trial: Pharmaceutical Care for the ElderlyThe 2.3
trial.over Time)
of Shared Prescribing for Elderly people in the Community (Randomised Evaluation 
ng data from the RESPECT next section I attempt to illustrate these concepts usi
type of regression models chosen i.e. a move towards the GLM framework.  In this 
decision makers.  This change in end product however may have implications for the 
d in formats which are meaningful to implication of these results in metrics an
move beyond producing tables of coefficients with hypothesis tests to producing the 
requires an extension to the way results are produced; the econometrician needs to 
ostly This m.  frameworkthis highly specifiedtechniques chosen must fit in within
in order to be policy relevant, the econometric economic evaluation in health and 
given the framework and requirements for,This section has thus argued that
relevant values of MWTP.
e used to construct a curve over all different willingness to pay for an effect and can b
35
impact on health related quality of life, as measured by the SF36 and achieved small 
d some 2001). The results of the study suggested that PC haBernstein,month period (
-randomised controlled longitudinal clinical trial with repeated measures over an 18
Pharmaceutical care of the Elderly in Europe Research (PEER) study was a 
this population. The to simultaneously assess the health outcomes and costs of PC in
of just one randomised trial that has attempted 1998). The RESPECT team are aware
,et alKennie assessment of the cost effectiveness of PC in an UK elderly population (
ating to the prospective literature relthere is relatively little2000),,et al(Bond 
potentially achievable by implementing pharmaceutical care in specific populations 
population. Moreover, whilst modelling studies have suggested that savings are 
es or are specific to an elderly the US and few come from community pharmaci
2003), evidence is predominately from ,et alpatients with specific diseases (Crealey 
hilst there is evidence that systems of pharmaceutical care can benefit However, w
include some element of pharmaceutical care.services could 
services commissioned locally by Primary Care Trusts (PCTs). These enhanced 
allows for nationally set essential and advanced services and enhanced ,April 2005
went live in , which Services Negotiating Committee and the NHS Confederation
ical for England and Wales between the Department of Health, the Pharmaceut
Moreover, the new contractual framework for community pharmacy that was agreed 
term drug treatment of patients. -should take on the extra role of looking after the long
that pharmacists 1999) recommends,In addition, the Crown Report (DoHpatients. 
vide ‘pharmaceutical care’ for their recommend that UK pharmacists prociation Asso
he Royal Pharmaceutical Society of GB and the UK Clinical Pharmacy Both t
and improve patients’ quality of life. 
related problems, -outcomes.  This has the potential to reduce the drug bill and drug
therapeutic compliance and concordance with treatment, and achieve specified 
PC aims to improve communication, promote ,making-patients in decision
implementing and monitoring a ‘pharmaceutical care plan’ (PCP).  By involving 
octors, patients and carers in designing, operate with d-doing so pharmacists co
moderating their drug care.  In their patients, pharmacists take a greater role in of
care be ultimately responsible for the (PC).  In this system, while doctors continue to 
proposed a system of ‘pharmaceutical care’ 1989) (Hepler and Strand,In the US
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the perspective of the health service and include all NHS costs and community 
Costs are evaluated from to receive the intervention were excluded from the analysis. 
datients who died before being randomisePused the EMIS medical records system.
randomised to receive the intervention and who were registered with GP practices that 
effectiveness analysis is based on patients alive at the time they were -The cost
the PCP.alternative treatments. PC involves the setup and monitoring of 
the identification of potential drug interactions, appropriate doses and feasible 
related problem and -medications, the establishment of therapeutic goals for each drug
he patients history and , 2010), but in brief, consisted of a detailed record of tet al
Pharmaceutical Care Plan (PCP). The PCP is described in detail elsewhere (Richmond 
operate with doctors, patients and carers in designing, implementing and monitoring a 
-in which pharmacists coThe intervention is the provision of ‘pharmaceutical care’ 
4.-Figure 2seefollowed up until May 2005, 
ere intervention in March 2003 and the last in September 2003. All patients w
irst PCT being randomised to receive the lasted a period of 12 months; with the f
and so acted as controls. All patients were recruited by May 2002. The intervention 
received training, community pharmacists provided their usual dispensing services 
ervention in a random sequence.  Until each group controls until they received the int
patients) began pharmaceutical care in five successive phases.  All five acted as 
Each PCT (the five groups of practices, pharmacies and their consent to take part. 
ome, well oriented in time and place, and able to give required), who were living at h
with repeat prescriptions for five or more drugs (excluding drugs taken only when 
aged more than 75 years and East Yorkshire were recruited. Eligible patients were 
es, from each of the five Primary Care Trusts (PCT) in North community pharmaci
general practices, each associated with about three 24time series. 760 patients from 
randomised multiple interrupted cluster trial design is a pragmatic RESPECT he T
Statisticsand DescriptiveTrial Design2.3.2
effectiveness. -cost
imates of any attempt to synthesise the data on cost and health outcomes to produce est
2003). However, the study did not make ,et albut insignificant cost savings (Sturgess 
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a cost per unit to the drugs prescribed as recorded on the prescription (i.e. strength, 
and applying ug tariffdrappropriate t.  Medications were costed using theeach patien
For each resource element, costs were aggregated by month for appropriate unit cost.
the A&E visits over the same period. Each resource element was valued by 
ified all inpatient hospitalisations, length of inpatient stay, outpatient visits and ident
(or electronic paper records if letters were scanned on to the EMIS data base). This 
resource use was identified by manually checking each recruit’s paper medical record 
GP or nurse and telephone calls to the GP or nurse.  In addition, secondary care 
to see a doctor, nurse or to attend a primary care clinic, all home visits made by the 
laboratory tests ordered through primary care, all visits to the general practice surgery 
2005 included all medications prescribed (acute and repeat prescriptions), all May 
items that were downloaded from the EMIS databases for the period May 2001 to 
and supplemented by examination of the patients’ paper medical records. Resource 
Resource use was downloaded directly from the EMIS database within the practice 
.  l’ period)contro-(this is henceforth referred to as the ‘preintervention costs-pre
use data were available for identifying the -worth of resource-that an additional year’s
the period May 2001 to May 2005. Given that the trial began in May 2002, this meant 
ecords for Health service resource use by patients was obtained from general practice r
pharmaceutical care visits.
locum cover were varied to the extremes of no locum cover and locum cover for all 
all home visits. For sensitivity analysis, the assumptions regarding and the recruit, and 
up visit between the pharmacist -cover the pharmacist’s time spent on the initial set
appropriate unit cost. For the base case analysis, it is assumed that a locum would 
sting the intervention, the time in minutes was multiplied by the basis. In co
meeting with the recruit. This information was sent to the trial office on a monthly 
GP to discuss the care plan was recorded. Pharmacists recorded these data after each 
monitoring visit. In addition, the time spent liaising with the patients between each
amount of additional time spent dealing with the patients pharmaceutical care plan 
Pharmacists recorded the amount of time (in minutes) spent with each patient and the 
QALYs.
5D instrument to -years using the EQ-adjusted life-terms of qualitymeasured in
pharmacy costs. All costs are presented at 2004/5 prices.  Health outcomes are 
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These to death and a negative score indicates a state of health that is worse than death. 
health, a score of 0 is equivalent y score of 1 corresponds to perfectassigned. A utilit
245 possible health states, for which a global value (i.e., a “utility score”) is one of
A recruit’s response effectively locates them into od and at the end of the trial.peri
at recruitment, at the start of the intervention, 3 and 12 months into the intervention 
5D questionnaire at five time points throughout the study: -completed an EQPatients 
ointsPollection Cata Design and Utility Drial : RESPECT T4-2Figure 
provided by the Hull Royal Infirmary.
cluding blood tests, were costed using published estimates in combination with data in
was not specified, a cost of a practice nurse clinic visit was applied. Laboratory tests, 
costed by type of consultation and location of consultation. Where the type or location 
er diem cost to each day spent in hospital. Primary care consultations were specific p
-length of stay based on the admission and discharge dates and applying a specialty
resources were costed by specialty. Inpatient care was costed by calculating the total 
ad been discontinued the latest available price was applied. Secondary care the drug h
dose and drug name). In addition, a dispensing fee was applied to each item. Where 
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220.00 (1208)240.00 (1179)190.00 (1000)149.00 (643)Total
132.90 (991)151.70 (1252)107.10 (794)71.90 (557)Secondary Care
23.00 (46.70)23.50 (41.70)19.30 (34.20)21.50 (39.60)Primary Care
4.36 (17.42)4.50 (17.51)3.47 (15.24)3.13 (14.69)Laboratory Results
52.70 (71)52.40 (129)53.90 (274)(280)46.20Repeat Medications
7.16 (30.30)7.99 (35.00)6.74 (22.70)6.75 (26.00)Acute Medications
Interven-PostInterventionControlControl-Pre
Unadjusted Monthly Costs by Trial Period. Mean (SD) £: 2-2Table 
13.5%Withdrawn during observation
3.84%Deaths during observation




Trial Descriptive Statistics: RESPECT 1-2Table 
population.
the sample descriptive statistics for the trial sshow3-Table 2through 1-Table 2
control period.
control period from the -U1 is the point which separates the preand 12 months).
the intervention period (0, 3 the intervention period as they were collected relative to 
through U4 depend on when the PCT started however utility points U2,respectively
t 13 and 48 months be seen all patients had their first and last utility collection taken a
e relevant PCT.  As can th utility data collection for a patient in thxx represents the U
y data collection points where shows the fixed and staggered nature of utilit4-Figure 2
(QALYs).
adjusted life years -years in order to calculate quality-scores are used to weight life
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However if data are Missing Not At Random (MNAR) then ignoring this missing 
, 2003).et alBriggstechniques used will accommodate these missing mechanisms (
dom (MCAR) or Missing At Random (MAR) then the maximum likelihood Ran
out is Missing Completely At -implications for the econometric modelling.  If drop
out process and the -not to participate.)  Thus some comment is possible on the drop
illness; and the remaining 38% to other reasons (e.g. spouse dying, or general wish 
to patients moving to nursing homes or to addresses outside the trial area;  27% due 
withdrawal obtained where possible.  Of the withdrawn patients: 35% were due to 
period).  Withdrawals were followed up by the research team and reasons for the 
e observation attrition (not due to death over th(full) a 13.5% rate of general there was
and there is a high degree of attrition in respondents.  In recruitment and baseline) 
(with the only tangible dip being between virtually unchanged over the time period 
values are time.  However the differences are not statistically significant, the median 
effective intervention as you would expect the natural course of utility to fall over 
before falling again when the intervention is finished.  This is indicative of an 
tervention from recruitment to baseline then an increase over the period of the in
show a decrease in mean values 5D -The descriptive utility scores as obtained by EQ
per patient monthly cost.
ndary care costs (i.e. hospitalisations) appear to be the major drivers of model.  Seco
underlying upward trend in costs that should be taken into account by the regression 
intervention period indicating that there may be an -costs over the early non
As can be seen there appears a general increase in monthly health cost outliers.  -high
a number of are also skewed with costs distribution of the he shown in the table, t
Although not the dependent variable in the regression models).  isvariable (which 
The descriptive statistics show the some of the major contributors to the total cost 
0.2690.6890.596432Final    U5 
0.26100.690.60045212 Months  (end of PC)U4 
30.27890.6860.55033 Months  (during PC)U3 
60.2820.68670.5532Baseline   (before PC)     U2 
60.270.69100.58611Recruitment                    U1 
SDMedianMeanN
eriodPrial Tby ScorestilityU5D -Mean, Median and Standard Deviation of EQ: 3-2Table 
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incorporating time.  
statistical analysis following the experimental design requires some means of formally 
up and include in the intervention estimate the negative effects of aging.  Thus the 
l inadvertently pick then a simple one variable analysis of the intervention effect wil
declines and they are more likely to require more hospitalisations, prescriptions, etc. 
time from the analysis may induce bias.  If we expect that as patients age their health 
thus omitting not particularly reasonable to assume that time has no causal effect, and 
intervention variable and time.  As we are dealing with elderly patients it is therefore 
control observations before the intervention then there is a correlation between the 
he trve related characteristics as a source of bias.  However due to the fact we obse
patients and thus (in the absence of attrition) eliminates omitted experimental unit 
intervention is independent of the characteristics of the PCT and the individual 
o control or individual (i.e. the data are longitudinal) and that the allocation t
observations.  The design ensures that we observe multiple observations per 
intervention) -months, before a final period of control (or perhaps more precisely, post
rvention regime for 12 conditions before they are cluster randomised into the inte
we observe observations from individuals (in clusters of PCTs) under control 
series.  That is -The experimental design of this analysis is a cluster interrupted time
Econometric Framework2.4.1
Modelic Econometrof Pharmaceutical Care 
Effectiveness -Estimation of the Costs, Benefits and Cost2.4
refinements needed to the econometric model.
assumption that attrition is mostly MAR or MCAR and there are no further 
trial and is a random event, we proceed on the cancer is independent of the
shows that cancer is the single most listed ailment, on the assumption that the onset of 
falls into the area of MNAR.  However further inspection of the withdrawal reasons 
d with an outcome measure (costs) then this potentially measure (QALY) or correlate
individuals who withdrew from the trial due to illness.  As illness is partly an outcome 
or the general attrition group may be classified as ignorable, this still leaves some 20 
mates.  Assuming that attrition due to moving away mechanism may lead to biased esti
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interest that is neither a cost nor a benefit, is the probability of death and is modelled 
regression framework as opposed to retransformation.  Finally a further outcome of 
ty outcomes that are not zero or one, we use GLM nature of the cost and utili
that a difference has occurred.  To deal with the skewed heteroscedastic and bounded 
of an individual reporting perfect utility and then expected difference from 1 given 
.    Similarly for utilities, we estimate the probability zero cost-expected value of a non
a given month is then given by the probability of a cost occurring multiplied by the 
zero cost.  The expected cost in -expectation of a cost conditional on there being a non
ccurring in a particular month and then model the probability of say a cost o
part model.  That is, we model the -nature of outcomes we model them as a two
modal -and skewed. We deal with these data issues as follows: to account for the bi
modal -nstrates similar properties being bounded (this time by 1), bi5D demo-the EQ
negative distribution.  Utility, as measured by -skewed, heteroscedastic, strictly non
modal distribution with a spike at 0 and a -of the cost outcome variable shows a bi
combination of theory and data considerations.  For example, the nature resolved via a
such as the choice of regression technique and the means of modelling time, these are 
However, adoption of the DiD framework still leaves a number of modelling issues 
attributed to an intervention over a given time period. 
fits that may be we may estimate the incremental differences in costs and bene
analyses: once we have a formal means of identifying counterfactual transition rates, 
effectiveness -separate transition paths makes it a natural means of informing cost
licitly identifying these However, the emphasis of the econometric model on exp
than the choice of a particular regression technique such as Ordinary Least Squares. 
difference in the difference).  DiD thus represents an approach to modelling, rather 
t/programme conditions (i.e. the the transition that would occur under treatmen
Such models work by estimating a natural transition over time (i.e. the difference) and 
outcomes over time, even when there may only be two time points: before and after. 
DiD models is the formal modelling of , 2004).  The key component ofFrölich(
identification strategy in the assessment of the effects of treatments or social policies 
Difference regression model (DiD).  DiD econometric models are considered a main 
-in-mplement in this research is the DifferenceFor this reason, the analysis model we i
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Finally as it is not clear how utility data are conducted on the remaining 599 patients.
should not have their utility or cost data included in the trial analysis, thus cost and 
otocol stated that patients who died prior to the intervention starting (30) The trial pr
emental difference.thus a means of calculating the incr
one, gives the expectation for the same individual under intervention conditions and 
with the same variable values with the exception of the intervention dummy set to 
hazard or survival function. Repeating this process natural/control hazard, cumulative
repeats, time and setting the intervention dummy to zero and calculating the 
regression results/estimates, plugging in some values for age, gender, number of 
onditions as implied by the regression model i.e. by taking the under different c
given time point may then be calculated by taking the expected values of the outcome 
dummy.  Note that the incremental effect of the intervention on an individual at a 
D approach is implemented by the inclusion of this latter intervention month.  The Di
prescriptions and a dummy variable indicating whether the month is an intervention 
fit with the following explanatory variables: a patient’s age, gender, number of repeat 
parametric model was Weibullt which patients are at risk of death.  Atime interval a
the first 12 months of observed data, the survival analysis takes month 13 as the first 
period, they are excluded from the analysis, and there are thus no recorded deaths in 
the research protocol excluded individuals who died in the control period.  As control
Survival is modelled using all 629 patients who were alive at the beginning of the 
Expected difference from perfect utility given a difference occurs
Probability of perfect utility
Expected cost given cost has occurred
cost occurringProbability of a 
Survival 
models in a DiD framework.
Thus the econometric component of the analysis consists of five conceptually separate 
framework are that costs and utilities are set to zero.
plications of death for costs and benefits within this using a survival analysis. The im
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impact will depend on the value of their other characteristics.  Observations were 
, the impact of that estimate will be different across individuals as the marginal month
stimate a single parameter for say linear although the model will e-the models are non
change, captured by the time intervention interaction.  It is important to note that as 
related -as a time consistent shift captured by the intervention dummy and a time–
mental effect of the intervention captured by the quadratic time variables; and the incre
linear transition over time -patient and PCT random effects); a natural/control non
observable characteristics (age, gender and number of repeats) and unobservables (the 
ents’ cost and utility based on allows for heterogeneous starting points for pati
level giving PCT and patient specific constant terms.  The specification of the model 
).  Random effects are estimated at patient and PCT int_monthintervention month (
d set to the value of month if it is an month is not an intervention month an
); and an month intervention interaction set to zero if the interintervention period (
); and intervention dummy set to one if the month is in the month_sqmonth squared (
); month); the month number (norepeatobservation (having at the start of the period of 
); the number of repeat prescriptions the patient is recorded as sexpatient is female (
); gender dummy variable set to one if the agestart of the period of observation (
survival models are: a patients age at the -ll nonexplanatory variables contained in a
The linear. -commonly used with the Gamma distribution and makes the model non
skewed and heteroscedastic.  The link function chosen was the log link which is 
as chosen on the grounds that it is bound by zero and may be Gamma distribution w
suited.  For the ‘costs’ and ‘differences from one’ models, the -and logit were not well
costs or perfect utility was relatively scarce and the symmetric properties of probit -no
obit link functions was on the grounds that the outcome of more common logit or pr
(cloglog) link function.  The adoption of the cloglog link function as opposed to the 
log -probability models the distribution chosen was Binomial with complementary log
For the two .  Hesketh, Skrondal, and Pickles 2004)-(RabeStata package for
gllammsurvival models were estimated using the -within patients and PCTs.  All non
level setting to incorporate the clustering of outcomes -Models (GLMs) in a multi
The remaining four regression models were all estimated using Generalized Linear 
intervention ended was not used in the model.
contamination of pharmacist behaviour) then data collected after the -the post














exponential model was rej
properties are better understood amongst the target audience.  An even simpler 
264) but the Weibull model is chosen as its -263 as opposed to -likelihoods of -(log
survival models had a marginally superior fit to the Weibull model logistic-and log
normal -on fit and other considerations such as ease of interpretation.  For example log
Numerous regression models were estimated and the final choice of models is based 
egression ResultsR2.4.2
.relationship
trial and so we implement a linear extrapolation beyond the time frame of the
linear transitions between these time points.  This approach would not permit any 
quadratic relationship but to estimate dummies for each of the time points and assume 
ing this may have been to impose no linear or which we have no data.  One way of do
the year.  This requires us then to have some measure of utility at time points for 
requirements of the economic evaluation require us to estimate the utility throughout 
time points, but the four tility is available on on umuch of the data.  Secondly, data
a quadratic relationship from just 12 data points (on costs) may have been asking too 
dependent effect of the intervention.  Attempting to obtain -which to estimate the time
onship, but only twelve discrete months from from which to estimate a quadratic relati
discrete months per patient tion.  For example, there are up to 43for economic evalua
is motivated by the periods for which we observe observations and the requirements 
ope possible difference for the intervention, simpler linear constant and straight line sl
The parameterisation of time in the model, as a quadratic natural progression and a 
converge  
were used for both patients and PCT level but not practice level as the model failed to 
.  Similarly random effects correlation between parameter estimates across outcomes
separately.  The estimated parameters will still be unbiased however there will be no 
, however the likelihood would not converge and the outcomes were modelled gllamm
ing the mixed response options in would have been modelled simultaneously us
zero cost or difference from perfect utility. Ideally all the (GLM) outcomes -was a non
of observation and in the expectation models if the patient were still alive and there 
he patient were still alive at the time included in the probability regression models if t
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147730-5558.92-722.60360.83-264.45-likehd-Log
0.02 (0.01)(0.01)0.14 0.02 (0.01)0.00 (0.00)PCT RE
0.34 (0.01)1.06 (0.05)0.17 (0.01)8.62 (1.73)Pat RE 
1.75 (0.18)
0.01 (0.00)-0.03 (0.01)-0.01 (0.01)-0.01 (0.09)-PC Month
0.14 (0.03)0.39 (0.06)0.03 (0.06)0.76 (0.77)0.02 (0.23)PC
0.01 (0.01)0.07 (0.01)-0.00 (0.03)-0.36 (0.39)Month Sqd/100
0.01 (0.00)0.03 (0.00)0.00 (0.02)0.19 (0.21)-Month
0.13 (0.01)0.03 (0.01)0.05 (0.01)(0.10)0.45-0.18 (0.04)No. Rx
0.03 (0.00)0.08 (0.01)-0.01 (0.00)0.06 (0.05)-0.09 (0.02)Age
0.19 (0.03)-0.31 (0.04)0.08 (0.03)0.47 (0.32)-0.88 (0.23)-Sex










CostP(cost Utility LossP(Utility =1)Survival
)Statistically significant results in bold,Standard Errors in brackets(
Regression Results: RESPECT Trial 4-2Table 
the other three models.
ith the modelling approach used in in the binomial utility model so it is consistent w
level effect, statistically significant in three of the four models.  The PCT RE was kept 
effects at patient level was justified in all four models and the use of a higher PCT 
GLM models the use of random boundaries of 1 and 0 respectively.  In the four 
heteroscedasticity and the inability of OLS models to incorporate the natural 
link GLM models were preferable to OLS models on the grounds of fit, -Gamma, log
symmetric models.  The -cantly better for the noncosts with model fit being signifi
models which identified whether there was a 1 in utility or a deviation away from 0 in 
significant.  Additional sophistication was warranted however for the binomial 























in the Weibull regression was statistically different from 1 (the null hypothesis 
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loss, the effect is negative (less loss) and increasing in magnitude over time. 
elow zero).  In terms of utility at which the intervention effect is predicted to fall b
positive (indeed it would be at month 55, a time point well outside the sample period, 
is positive but declining over time, within a 12 month period the effect is estimated as 
fect of the intervention For the probability of reporting perfect utility the efby time.  
given time is a function of the constant dummy plus the slope coefficient multiplied 
Similarly the incremental impact on the linear component of the intervention at any 
a loss increases.perfect utility falls and the loss where there is
down: the probability of –over the 43 months is unambiguously in one direction 
within sample period of 43 months, the utility loss very gently rises.  The net effect 
o 40 months before declining.  Over the a utility loss, gently increases over time t
The amount of utility loss over time, given that there is recording perfect utility falls.  
.  Over the period of 43 months, the probability of a patient againstarting to rise
nes from month 1 to month 26 before the probability of perfect utility decliFor utility, 
impact over the 43 months of data is of an increasing trend in costs.
The overall given that a cost has occurred is always increasing over the time frame.
ining but the impact on the amount of a cost, maximised at 24 months before decl
The values are such that the impact on the probability of a cost occurring is 
cost variable, the probability is increasing with time but decreasing with time squared.  
time frames).  For example with the probability of a points (and indeed over different
take into account the values of more than one parameter evaluated at different time 
In terms of the transitions over time, the picture is more complicated as one has to 
direction.
nt in all cases and always in the ‘right’ number of repeat prescriptions is significa
surprising as the fewer number of observations reduces the power of the test.  The 
significant results occurring most frequently in the utility regressions.  This is not -non
nerally statistically significant with Results are gecost given that a cost has occurred.
a cost/resource use per month and a higher ility, a higher probability of incurringut
report high deviations from ,higher hazard of dying, less likely to report perfect utility
numbers of repeats have a ly patients and patients on greaterstarting points, elder
The regression results are broadly in line with a priori expectations.  In terms of 
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female patient with 7 repeats (average characteristics for a member of the study 
.  Thus for an average 80 year old )9:(expy log link models the inverse is simpl and for the ))9:(exp
(exp
1For the cloglog models the inverse link function is
.)<:9(,=
)<:9(,=combinations i.e. 
effect in an original metric one must apply the inverse link function to both linear 
linear.  To understand the incremental-the inverse link function as the model is non
point, but it does not represent a difference on a meaningful scale even if put through 
represents the difference in the linear component at any given time <:9
<:9husT
dummy is set to one and the intervention time interaction set to the relevant month.  
same individual over the same time scale with the exception that the intervention 
, for the <:9then create a linear combination,I the relevant regression equation.  from
are the estimated coefficients <:intervention time interaction set to zero, where the 
each month that we wish to evaluate (0 to 12), with the intervention dummy and 
for <:9create a linear combination set of given characteristics Ia patient with aor F
transitions over time.
of the random effects i.e. zero) and show the differences in their starting points and 
individuals with differences in their observed characteristics (I assume the expectation 
illustrative cases representing als we present fourent individube different on differ
transformation bias and the predictions are unbiased.  As the incremental effect will 
-entered the regression model in their original untransformed metric there is no re
ons.  As GLM has been used and the outcome variables under intervention conditi
original metric via the inverse of the link function for individuals under control and 
For this purpose we convert the linear functions to the expected outcomes in the 
.  in a meaningful metricdifference the intervention has madeexpected incremental 
and not the 9:, they show the estimated linear componentand general trendstestinglthough the regression results are informative and may be used for hypothesis A
Deterministic Expectations2.4.3
to calculate the impact over time.surprising given the lack of data points, especially
The lack of significance of several of the parameter values in the utility models is not 
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systematic differences in expectations rather than produce a representative sample.
note the choice of individuals is to identify –in the trial to the most frail the healthiest
nce in outcomes for a set of individuals ranging from expected outcomes and differe
random effect for the individual is set to zero.  The diagrams therefore show the 
By average I mean that the and an average 90 year old female with 15 repeats.  
with 10 repeats female an average 85 year oldent with 7 repeats; year old female pati
for an average 75 year old female with 5 repeats; an average 80 and expected costs
utility costs expected show the probabilities of survival; 7-Figure 2through 5-igure 2F
.}>)9:(exp
{exp =)>(by tity of being alive in a given month component is converted to a probabil
The effect on the probability of survival is conducted in a similar manner, the linear 
there is approximately no incremental effect in month 12.
f a cost occurring by 5% in the first month which steadily declines until probability o
the intervention over time.  Thus for an average patient the intervention increases the 
and it is the difference in these probabilities which represents the incremental effect of 







atientPverage Aor an Probability of a Cost Occurring Over Time f:5-2Table 
5.-Table 2shown in 
population), the expected transition over time of the probability of a cost occurring is 
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ntuitively appealing with expected Comparing across individuals, the results here are i
multiplied by the expected utility loss if a utility loss occurs.;reporting perfect utility
one minus the probability of individual is alive at that time point; multiplied by 
: the probability that the the mathematical expectation ofas derived by over time 
shows the expectations of reported utility for the same average individuals 6-Figure 2
difference attributable to the intervention.
etely overlapping survival curves show that there is no substantive almost compl
As expected from the regression results the graphs rather than between the graphs.
expectations under control and intervention conditions i.e. the difference within the 
erest, the intervention effect, is captured by the difference between the impact of int
probability of dying in any given month relative to the 75 year old.  However the 
expectations in that a 90 year old with many repeat prescriptions has a higher 
The results are in line with a priori .  axis runs from 1 to just below 0.9)-the y
(though notice the scale of between individuals with differing observed characteristics
difference in the probability of survival shows the clear systematic 5-Figure 2
Over TimeProbability of Survival:5-2Figure 
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number of prescriptions.  
the incremental effect is clearly largest for the elder population with the greater 
s to higher costs and specifically higher costs at the beginning of the intervention, lead
systematically differs across types of individuals.  Although the intervention always 
of the intervention.  Unlike utility the incremental effect of the intervention 
number of repeat prescriptions and like utility, there is a clear incremental effect and
survival and utility the graphs show an intuitively correct picture rising costs over age 
and is calculated in an analogous manner to utility (survival*prob cost*cost).  As with 
shows the expected costs over time for the four representative individuals 7 -Figure 2
ver TimeOExpected Utility : 6-2Figure 
case.utility with the incremental effect being broadly similar in each 
higher expected the latter six months of the period with the intervention suggesting 
over expectations predicted under control and intervention conditions.  Specifically
between the utility here we can see daylight –that the intervention makes 
occurs when we consider the differences within individuals 5-Figure 2difference to 
The as we move from the healthiest to the frailest individual.utility declining 
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approximately 7 days in perfect health), the statistic of interest from a NICE 
Although these are relatively modest changes (0.02 QALYs represents + £703).to
thiest (+ £89 healcosts is nearly 9 times higher for the frailest group compared to the
+ 0.020) attributable to the intervention whereas the difference in totypes (+ 0.016 
that there is a pretty much constant incremental effect in QALYs across population 
and confirms 7-Figure 2nd6 a-Figure 2The table quantifies the picture portrayed in 
£35,185£703£4977£42740.0200.3830.36390 year old with 15 repeat drugs
£17,980£302£2510£22070.0170.5370.52085 year old with 10 repeat drugs
£9,515£155£1566£14110.0160.6200.60480 year old with 7 repeat drugs
£4,661£89£1080£9910.0190.6800.66175 year old with 5 repeat drugs
PCUsualPCUsual (£/QALY)
ICERCosts (£)QALYs
earYver a Oifferences Totals and Incremental DExpected:6-2Table 
ver Time: Expected Costs O7-2Figure 
age*prescriptions population.
period and the associated ICER for the average representative of that 
summed over a 12 month shows the expectations of costs and utilities 6-Table 2
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across individuals of the population.  Given the nature of of the intervention effect 
systematically different One final note should be made on the implications of the 
the individuals and averaged across the population. 
relatively modest effect of the intervention on both expected costs and QALYs across 
.  The analysis shows the per QALY10,000£Effectiveness Ratio (ICER) of -Cost
ntal .  Giving an Increme92£1with an incremental cost increase of QALYs 90.01
he population averaged incremental effect of the intervention was an increase of T
characteristics such as age or gender.
the individual specific random effects as if they are fixed That is we treatand PCT.
cost and utility regressions, including the estimated random effects for each patient 
averaged effect across the 599 patients who were part of the -we report the population
which we believe to be representative, ter the population As we have no reason to al
correcting for differences in population.
effectiveness parameters via a regression model provides a reasonable means of 
-population is thought to be different to the study population, then obtaining the cost
out -less if the rollolds with 2 or fewer repeat prescriptions).  Neverthe-50 yr
whose characteristics are beyond those that were used in estimating the results (e.g. 
population, although it would be unwise to apply the regression results to individuals 
lysis to a hypothetical data generating mechanism is uncovered one may apply the ana
scope in defining the population and is not restricted to the study population.  As the 
n calculating the average effect across the population the analyst has some However i
of the expectations.patient will not be the same as the average
produce an expectation for the average patient as the expectation of the average 
linear it is not sufficient to -As the models are nonpopulation which is required. 
across the averaged these differences tive it is pecFrom a societal decision making pers
one that would be outside that usually reimbursed.
a range well under the NICE threshold to –£4,661 per QALY to £35,185 per QALY 
anges can have a relatively large effect.  In this case the expected ICERs range from ch
perspective is that of the ICER and as QALYs enter as a denominator, then small 
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of the parameters around their expected values does not equate to an assumption of a 
interpretation of a frequentist matrix.  The assumption of normality of the distribution 
covariance matrix, a Bayesian -parameter uncertainty is characterised by the variance
This approach thus assumes the .st statistical packages though easily recoverablemo
regression parameter estimates.  This matrix is typically hidden in the background in 
covariance matrix of the -defined by the parameter estimates and the variance
from a multivariate Normal distribution with expectations, variance and covariances 
models s for all variables in the regression <:regression model, we simulate a set of
s contained in the <:i.e. instead of just using the point estimates of themodel 
parameter values with a probability derived from the standard errors of the regression 
native .  A Monte Carlo simulation method is used to provide alterexpectations
means of constructing the CEAC are similar to those used to produce the 
detailed.  The practical previously We will illustrate the uncertainty using a CEAC as 
urrounding the estimate.consider the probabilistic uncertainty s
very small effects may cause decision makers to exercise their prerogative and 
primarily be base on the value of the ICER as it is under £20,000, the estimates of 
n the NICE Guide indicates that a NICE decision will analysis.  Although 6.2.6.10 i
Economic evaluation of health care technologies require probabilistic sensitivity 
Probabilistic Sensitivity Analysis2.4.4
trial population.
effects of the intervention on a wider population making small extrapolations from the 
he this chapter, but the regression results produced could plausibly used to estimate t
receive the intervention and have the lowest ICER of all.  It is beyond the scope of 
(slightly less than 75 or with fewer repeat prescriptions) who would potentially 
ation plausible that trial design has omitted the effect on some members of the popul
that had the biggest expected health gains and the lowest increase in costs, then it is 
bitrarily drawn a line at age 75 and 5 repeat prescriptions, given that it as this group ar
not draw up PCPs for all patients).  However the nature of the evaluation has 
desirable) to deny the expertise to groups of patients (although presumably they will 
of patients, once a pharmacist has been trained then it is perhaps not possible (or even 
groups-PC, it is not one of those treatments that it easy to target towards specific sub
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clear in this case.
The issues which make the quantitative interpretation of a CI for a ratio are plane). 
Y gain (simulations located in the North West show a higher cost with negative QAL
effectiveness plane) and 5% -East corner of the cost-(simulations located in the South
outcomes show a lower cost of PC associated with a higher QALY outcome 
tion of the simulated results as more than 5% of the simulated qualitative interpreta
for the ICER is the The CIeffectiveness plane. -these simulations plotted on the cost
shows 8-Figure 2The upper half of the simulation results.  Bayesian interpretation of 




0.7360.4020.595QALYs in usual care
£579£150-£192Incremental Costs
£2,777£1,109£2,001Cost of PC








Sensitivity AnalysisSimulated Monte Carlo : 7-2Table 
construction of the CEAC. 
rmits comparing this against the paired simulated value of the incremental cost pe
and 
framework,  converting effects on QALYs to a monetary values according to
population averaged incremental costs and benefits recorded.  Adopting the NMB 
imulations with each used to produce a distribution of outcomes from multiple s
is onte Carlo simulation and the Mthe same procedure as the deterministic results
derived distributions may then be converted to expectations in the original metric via 
om draws from the estimation The new parameter estimates as defined by the rand
linearity of the model.-non
normal distribution of the effect on the original metric.  Again, this is a function of the 
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some rather extreme values.
results, a ratio constructed from two values fairly close to zero and the sampling of 
inty in the value lower than £10,000 as may be expected.  This is due to the uncerta
£8,500.  Accordingly the CEAC crosses the 0.50 probability line at a approximately 
,deterministic calculationthat of thedifferent to is CERsimulation mean I
that occurs because the The simulated results do throw up one slight surprise and
for costs.
to see that the need for greater evidence on utility exceeds that dissertation, it is clear
in this formal EVPPIthe costs is not surprising.  And although I do not conduct a 
rather than there is more uncertainty regarding the effectiveness of the intervention 
picture that discrepancies in the available evidence for these components, the overall
baseline utility points and 2 intervention data points for utility.  With such 
pared to just 3 transition of costs and 12 to estimate the incremental effect, com
utility.  There were 36 observations per individual from which to estimate a baseline 
of the levels of uncertainty that surround the estimation of the cost and that of the 
h 1 is a function zero and does not approacboveafrom (just) That the curve originates 
effective lies between 0.775 and 0.812.-cost
,  the probability that pharmaceutical care is consistent with NICE’s threshold range)
threshold between £20,000 and £30,000  per QALY (as is and converges to 0.85.  At a 
the MWTP for a QALY increases from £0 to infinity, the CEAC increases from 0.1 
effective, quantitative measures of limits have a clear and distinct meaning.  As -cost
CEAC shows the implied probability that the intervention is simulation data.  As the
hows the CEAC constructed from the same set of 8 s-Figure 2The lower half of 
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not shown here)
s; assuming the 
lausible values: 
ernative costing 
nal ioAdditums.  
two additional 
use if the GP or 
ultation with the 
GPs and nurses 
used within the 
s ptotes to 82% a
uggests that the 
EAC
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(n costs.  The univariate sensitivity analysis
ssuming the lower band of intervention cost
three assumptions at the boundaries of p
t the sensitivity of the analysis to altto tes
ts were produced on the basis of costing loc
hat time for some other activity.  Similarly 
.  This may not accurately reflect resource 
analysis as if the patient had had a full cons
e costing of Did Not Appear (DNAs) with 
with regards to the costing of resource 
ssumptionsAost nsitivity to C
=£20,000 and asym
to be cost effective a
the parametric uncertainty, the evidence s
Effectiveness Plane and C-on Costncertaintyt of U
interventiohigher band of 
costing DNAs as zero; a
regimes which represent 
were conducted analyses 
different intervention cos
nurse were able to use t
practice memberrelevant 
were costed in the main 
analysis.  For example th
There were some issues 
Univariate Se2.4.5
.intervention is 74% likely 
Nevertheless, even given 
: Simulated Impac8-2Figure 
simulated outcomes, the local maximum occurs at an earlier point around £8,500.
i.e. a local maximum at £10,000.  However as this graph is based on the changes
a local maximum at the point at which the decision is expected to haveThe EVPI 
: Expected Value of Perfect Information9-2Figure 
.
function o
which show EVPI per person as a 9-Figure 2cient to produce is suffi
 range o
and conducting the exercise across a 
 simulations gives the EVPI for that level o
world makes the choice incorrect and the cost of that decision.  Averaging across all 
may be used to identify the likelihood that the realisation of the individual simulations 
choice between intervention or traditional care.  Once the choice has been made, the 
an expected NMB may be calculated and a decision made for the 
 each level o
s are conducted using the simulated data in the following manner: for EVPI calculation
Expected Value of Perfect Information (EVPI)2.4.6
no change in decision is implied.
the analysis is largely robust to different costing assumptions and demonstrates that
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% of the time at a threshold value of £20,000 per QALY.be correct 74PC would 
.  Furthermore the PSA indicates that a decision to implement sufficient to reimburse
the range that a national body like NICE would consider the evidence to generally be 
.  This is in , with an ICER of £10,000effective in an elderly population in the UK-cost
ESPECT trial has shown that the evidence points to PC being The analysis of the R
Conclusions2.5
utility as the key parameter on which to focus future research.
Although not conducted here the EVPPI would be expected to identify the effect on 
ion of a large number of elderly population on many repeat prescriptions.  the assumpt
being a function of sThe high valueEVPI ranging from £99 million to £112 million.
This works out a population .individuals per yearenvelope population of 272,000 
s per practice (derived from original RESPECT data), this implies a back of the patient
with approximately 8,500 practices in England with a relevant population of 32 
5 years and respectively.  Assuming an intervention lifespan of is £78.04 and £88.27
mber of the population £20,000 and £30,000 the EVPI per meFor threshold values of 
probability is weighted by an increasing value of a QALY.
of the value of a QALY and hence the EVPI becomes a straight line as this constant 
intervention has a negative impact on QALYs.  This particular statistic is independent 
ly the probability that the probability of an error in decision occurring is effective
effect is that the EVPI initially falls.  As the value of a QALY increases, the 
value of a QALY increases, the likelihood of an erroneous decision falls.  The net 
, however as the larges relativelylocal maximum, the probability of making an error i
Around the maximum at the point at which the implementation decision switches.
the cost of making an error also increases and leads to the local making an error and 
the probability of f a QALY increases, incorrect decision is quite low.  As the value o












the conventional treatment.  
minimising option which is -oice is the costeffective ch-the cost
or small values oF
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ess, furthermore by (marginally) possibility in their decision making proc
implementation of the programme.  Decision makers may wish to incorporate that 
underestimated the benefits and overestimated the costs of the effects on a national 
n it is plausible indeed likely that the trial has trial (with the lowest costs).  The
may be affected, and given that it was the younger patients who benefited most in the 
intervention and that should the intervention be rolled out nationally, younger patients 
subset of the population that may receive the example, as the trial was limited to a 
for –characteristics and this may have important consequences for this study 
provided a means of identifying heterogeneity between individuals with differing 
th costs and QALYs.  However the econometric approach has uncertainty of bo
of would have been able to incorporate the correlation in the bootstrapping
unable to conduct PSA over both costs and benefits simultaneously, whereas a simple 
l transition over time and furthermore, because of convergence problems, I was natura
stage models and a quadratic form for the -analysis.  For example, I have assumed two
this may be seen as both a cost and a benefit whose magnitudes differ according to the 
–ence of using these techniques is that a formal model structure is required consequ
and use bootstrapping of evidence within the clinical trials to produce PSA.  One 
economic evaluation in place of simple analysis which compares means across groups 
The chapter has also illustrated that the techniques of econometrics may be used in 
es/is made available.evidence (particularly on the effect on QALYs) becom
intervention, but that this decision should be revisited in the future when further 
effective -the current evidence clearly points to a cost–conclusion becomes clear 
rms two distinct questions, then the criteria and accept that the evidence info
appeals to the underlying principles contained in the NICE guide and adopt Claxton’s 
relatively benign assumptions on population and lifespan of intervention.  But if one 
million based on approximately £100QALY, quite substantial at £20,000 per
surrounding the effect on QALYs and the large (and increasing) elderly population, is 
extent this is reinforced by the calculation of EVPI which, because of the uncertainty 
s has caused some unease in the audience.  To some team meetings and research forum
than relative) magnitude of these outcomes, presentation of these results in RESPECT 
per individual.  Although NICE draw no significance to the actual (rather and £192
average of 0.019 QALYs h period are rather modest at anutilities over a twelve mont
However the analysis has also identified that the incremental differences in costs and 
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methods.
means of addressing data issues that are beyond the reach of simple clinical trial 
ric model becomes a valuable circumstances the structure imposed by the economet
attrition or selection rules (i.e. randomisation may no longer be relied upon).  In those 
random -forward clinical trial data is being used such as trial data where there is non
ta other than very straight techniques in economic evaluation may well occur where da
estimate of how great this bias was. Thus the major benefits of using econometric 
extrapolating beyond the population of the trial it would be possible to achieve an 
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